Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04489407
Other study ID # 2021-2376
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date August 1, 2020
Est. completion date November 30, 2020

Study information

Verified date July 2020
Source Lady Davis Institute
Contact Noura Hassan, MD, MPH
Phone 514-340-8222
Email noura.hassan@mcgill.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Contactless and widely available health monitoring technologies are of growing interest in the context of the worldwide COVID-19 pandemic. Remote photoplethysmography (rPPG) is a well-studied technology that interprets variations in skin colour related to blood flow which, when analysed with complex mathematical algorithm, generates vital sign readings. This technology has been refined and embedded in a smartphone app designed to acquire heart rate, respiratory rate and oxygen saturation using a front-facing smartphone camera.

Preliminary data comparing the accuracy of smartphone rPPG readings with conventional vital sign monitor readings are promising; however, less than 5% of the population studied in the app development phase had oxygen saturation levels below 95% making it impossible to ensure reliability in these populations.

The goal of this study is to compare readings acquired using this rPPG app with the readings from hospital grade, Health Canada approved vital signs monitors used in healthcare settings with a focus on subject with low oxygen saturations. We will also study other sociodemographic and clinical features that may influence the accuracy of the readings. This will be achieved by recruiting consenting adults presenting to care in acute care settings and a designated COVID outpatient clinic. Vital signs will be acquired using the rPPG app and conventional hospital vital sign monitors simultaneously. Readings will be repeated within 2-5 minutes when time permits. Statistical analysis will be performed to analyze the findings and determine the accuracy and precision of the rPPG app readings.

It is expected that the vital sign readings acquired with the rPPG app will be almost identical to those acquired using hospital-grade monitors for all subjects regardless of age, gender, skin colour, COVID status and relevant comorbidities.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 350
Est. completion date November 30, 2020
Est. primary completion date October 30, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Persons willing to participate and capable of providing informed consent, age of 18 years of more.

- Person able to sit still for the duration of the reading (maximum 2 minutes per reading).

- Persons with freckles, discreet skin pigmentation changes

Exclusion Criteria:

- Unable to provide informed consent

- Persons who are unable to follow basic instructions due to altered mental status, delirium, dementia or other conditions.

- Age < 18

- Intubated patients and patients requiring masks for supplemental oxygen

- Persons refusing to remove masks, eyewear, or clothing obstructing the face for the duration of readings.

- Persons with facial tattoos, large birthmarks or other skin alterations (scars, hemangiomas) on their nose or upper cheeks (cheekbones).

Study Design


Intervention

Device:
Remote Photoplethysmography (rPPG) vital sign acquisition
Subject vital signs will be acquired using the rPPG app simultaneously with the conventional vital sign monitors and manual respiratory rate calculation.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Lady Davis Institute Carebook Technologies Inc.

Outcome

Type Measure Description Time frame Safety issue
Other Accuracy of rPPG readings by oxygen saturation level Analysis of accuracy of rPPG vital sign readings when stratified by oxygen saturation per conventional monitors stratified as follows: 95-100%; 90-94%; 85-89%; Less than 85% immediate; stratified analysis
Other Accuracy of rPPG readings by skin colour Analysis of accuracy of rPPG vital sign readings when stratified by skin colour per the Fitzpatrick scale immediate; stratified analysis
Other Accuracy of rPPG readings by gender Analysis of accuracy of rPPG vital sign readings when stratified for gender immediate; stratified analysis
Other Accuracy of rPPG readings by age Analysis of accuracy of rPPG vital sign readings when stratified by age group immediate; stratified analysis
Other Accuracy of rPPG readings by comorbidity Analysis of accuracy of rPPG vital sign readings when stratified for COVID, respiratory conditions, cardiac conditions and vascular conditions. immediate; stratified analysis
Primary Accuracy of rPPG heart rate Accuracy of rPPG heart rate compared to conventional vital sign monitor heart rate readings. Comparison of each paired reading. immediate; paired reading
Primary Accuracy of rPPG oxygen saturation Accuracy of rPPG oxygen saturation compared to conventional vital sign monitor oxygen saturation readings. Comparison of discrepancy within each paired reading set. immediate; paired reading
Primary Accuracy of rPPG respiratory rate Accuracy of rPPG respiratory rate compared to manual counting of respiratory rate over 60 seconds. Comparison of discrepancy within each paired reading set. immediate; paired reading
Secondary Reproducibility of rPPG heart rate readings Comparison of rPPG heart rate results obtained on a given patient on serial readings within 2 minutes of each other. 2-5 minutes
Secondary Reproducibility of rPPG oxygen saturation readings Comparison of rPPG oxygen saturation results obtained on a given patient on serial readings within 2 minutes of each other. 2-5 minutes
Secondary Reproducibility of rPPG respiratory rate readings Comparison of rPPG respiratory rate results obtained on a given patient on serial readings within 2 minutes of each other. 2-5 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT05971407 - The Effect of Chronic Remote Ischaemic Preconditioning on Blood Pressure in Older Adults N/A
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Recruiting NCT04390672 - Multivessel TALENT N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Completed NCT01684826 - X-ray Dose Reduction Study for Cardiac Angiography and Intervention N/A
Completed NCT01417910 - Predictors of Post Operative Outcome in Peripheral Vascular Surgical Patients N/A
Terminated NCT00935766 - Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries Phase 3
Unknown status NCT01748383 - The Long-term and Short-term Efficacy and Safety of Transplantation Autologous Bone Marrow Cells (BMCs) in Patients With the First STEMI (ST Segment Elevation Myocardial Infarction) Phase 2
Recruiting NCT05907564 - Aventus Thrombectomy System Pulmonary Embolism Clinical Study N/A
Recruiting NCT03732612 - Inflammation in Vascular Disease
Completed NCT00000614 - Prevention of Recurrent Venous Thromboembolism (PREVENT) Phase 3
Completed NCT00000530 - Raynaud's Treatment Study (RTS) Phase 3
Completed NCT00000479 - Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer Phase 3
Completed NCT00000539 - Arterial Disease Multifactorial Intervention Trial (ADMIT) Phase 3
Completed NCT00000474 - Prevention and Treatment of Hypertension Study (PATHS) Phase 3
Completed NCT00000528 - Trials of Hypertension Prevention (TOHP) Phase 3
Completed NCT00000509 - Potassium and Sodium to Control Blood Pressure in Hypertensives Phase 3
Completed NCT00000501 - Hypertension Prevention Trial (HPT) Feasibility Study Phase 2
Completed NCT00000499 - Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study) Phase 2